HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mountain, C. F. Search for Related Content PubMed PubMed Citation Articles by Mountain, C. F.

The Annals of Thoracic Surgery, Vol 40, 60-64, Copyright © 1985 by The Society of Thoracic Surgeons

ARTICLES

The biological operability of stage III non-small cell lung cancer

CF Mountain

Stage III non-small cell lung cancer represents a broad spectrum of anatomical and histological subsets of patients with differing biological characteristics and prognostic expectations. Our experience with 161 consecutive patients undergoing complete resection for Stage III non-small cell lung cancer at the M. D. Anderson Hospital and Tumor Institute from 1965 through 1980 includes 69 patients with T3 N0 or N1 disease and 92 patients with an N2 classification. The cumulative 5- year survival overall was 30%: 35.6% for the T3 N0 or N1 group and 26% for the N2 patients. Seventy-three patients had squamous cell carcinoma and 76, adenocarcinoma. Small numbers of patients had other miscellaneous classifications (N = 12). In the T3 N0 or N1 subset, 43% of the patients with squamous cell carcinoma (N = 37) and 23% of those with adenocarcinoma (N = 25) survived 5 years. In the N2 subset, 39% of the patients with squamous cell carcinoma (N = 36) and 14% of the group with adenocarcinoma (N = 52) achieved long-term survival. Failure of treatment was clinically documented in 61 patients. The first observed recurrence or metastasis was at a distant site in the majority of these patients. Operative intervention for patients with Stage III M0 non- small cell lung cancer is effective and reflects the impact and limitations of resection on disease progression. Adjuvant irradiation was not shown to improve the outcome over the results of operation alone. Effective systemic therapy will be required to produce substantial changes in end results.

This article has been cited by other articles:

				T-E Strand, H Rostad, B Moller, and J Norstein Survival after resection for primary lung cancer: a population based study of 3211 resected patients Thorax, August 1, 2006; 61(8): 710 - 715. [Abstract] [Full Text] [PDF]

				J. K. LeBlanc, B. M. Devereaux, T. F. Imperiale, K. Kesler, J. M. DeWitt, O. Cummings, D. Ciaccia, S. Sherman, P. Mathur, D. Conces, et al. Endoscopic Ultrasound in Non-Small Cell Lung Cancer and Negative Mediastinum on Computed Tomography Am. J. Respir. Crit. Care Med., January 15, 2005; 171(2): 177 - 182. [Abstract] [Full Text] [PDF]

				K. Okubo, T. Kato, A. Hara, N. Yoshimi, K. Takeda, and F. Iwao Imprint Cytology for Detecting Metastasis of Lung Cancer in Mediastinal Lymph Nodes Ann. Thorac. Surg., October 1, 2004; 78(4): 1190 - 1193. [Abstract] [Full Text] [PDF]

				K. Nagai, R. Tsuchiya, T. Mori, H. Tada, Y. Ichinose, T. Koike, and H. Kato A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209) J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 254 - 260. [Abstract] [Full Text] [PDF]

				M. Riquet, F. Le Pimpec Barthes, R. Souilamas, and G. Hidden Thoracic duct tributaries from intrathoracic organs Ann. Thorac. Surg., March 1, 2002; 73(3): 892 - 898. [Abstract] [Full Text] [PDF]

				M. Th. M. van Rens, A. Brutel de la Riviere, H. R. J. Elbers, and J. M. M. van den Bosch Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA Chest, February 1, 2000; 117(2): 374 - 379. [Abstract] [Full Text] [PDF]

				E. van Velzen, A. Brutel de la Riviere, H. J.J. Elbers, J.-W. J. Lammers, and J. M.M. van den Bosch Type of lymph node involvement and survival in pathologic N1 stage III non-small cell lung carcinoma Ann. Thorac. Surg., April 1, 1999; 67(4): 903 - 907. [Abstract] [Full Text] [PDF]

				R. Maruyama, K. Sugio, T. Mitsudomi, G. Saitoh, T. Ishida, and K. Sugimachi RELATIONSHIP BETWEEN EARLY RECURRENCE AND MICROMETASTASES IN THE LYMPH NODES OF PATIENTS WITH STAGE I NON-SMALL-CELL LUNG CANCER J. Thorac. Cardiovasc. Surg., October 1, 1997; 114(4): 535 - 543. [Abstract] [Full Text]

				T. Yano, H. Yokoyama, T. Inoue, H. Asoh, K. Tayama, and Y. Ichinose Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lungSignificance of N1 level: lobar or hilar nodes J. Thorac. Cardiovasc. Surg., June 1, 1994; 107(6): 1398 - 1402. [Abstract] [Full Text]

				P. Goldstraw, G. C. Mannam, D. K. Kaplan, and P. Michail Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease) J. Thorac. Cardiovasc. Surg., January 1, 1994; 107(1): 19 - 28. [Abstract] [Full Text]

				D. J. Malenka, G. L. Colice, C. Jacobs, and J. R. Beck Mediastinal Staging in Non-small-cell Lung Cancer Med Decis Making, December 1, 1989; 9(4): 231 - 242. [Abstract] [PDF]